A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ohkubo, 1995, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study, Diabetes Res Clin Pract, 28, 103, 10.1016/0168-8227(95)01064-K
Tan, 1999, Diabetes and coronary artery disease, Diabetes Spectrum, 12, 81
Haffner, 1999, Management of dyslipidemia in adults with diabetes, Diabetes Care, 22, S56
Fontbonne, 1991, Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Propective Study, Diabetologia, 34, 356, 10.1007/BF00405009
Reaven, 2000, Insulin resistance and its consequences: Type 2 diabetes mellitus and coronary heart disease, 604
Vosper, 2002, Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis, Pharmacol Ther, 95, 47, 10.1016/S0163-7258(02)00232-2
Kipnes, 2001, Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study, Am J Med, 111, 10, 10.1016/S0002-9343(01)00713-6
Miyazaki, 2001, Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone, Diabetes Care, 24, 710, 10.2337/diacare.24.4.710
Rosenstock, 2002, Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy, Int J Clin Pract, 56, 251, 10.1111/j.1742-1241.2002.tb11251.x
Dobiasova, 2001, The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)), Clin Biochem, 34, 583, 10.1016/S0009-9120(01)00263-6
Tan, 2001, Pioglitazone reduces atherogenic index of plasma, an indirect indicator of LDL particle size, Diabetes, 50, A133
American Diabetes Association, 2002, Standards of medical care for patients with diabetes mellitus, Diabetes Care, 25, 213, 10.2337/diacare.25.1.213
Aronoff, 2000, Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group, Diabetes Care, 23, 1605, 10.2337/diacare.23.11.1605
Rosenblatt, 2001, The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus, Coron Artery Dis, 12, 413, 10.1097/00019501-200108000-00011
Levy, 1998, Correct homeostasis model assessment (HOMA) evaluation uses the computer program, Diabetes Care, 21, 2191, 10.2337/diacare.21.12.2191
Hochberg, 1988, A sharper Bonferroni procedure for multiple significance testing, Biometrika, 75, 800, 10.1093/biomet/75.4.800
Miyazaki, 2002, Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes, Diabetes Care, 25, 517, 10.2337/diacare.25.3.517
Radziuk, 2000, Insulin sensitivity and its measurement: Structural commonalities among the methods, J Clin Endocrinol Metab, 85, 4426
Bonora, 2000, Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degress of glucose tolerance and insulin sensitivity, Diabetes Care, 23, 57, 10.2337/diacare.23.1.57
Matthews, 1985, Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883
Huang, 2001, The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus, Am J Med, 111, 633, 10.1016/S0002-9343(01)00978-0
Gu, 1998, Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993, Diabetes Care, 21, 1138, 10.2337/diacare.21.7.1138
Kannel, 1985, Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study, Am Heart J, 110, 1100, 10.1016/0002-8703(85)90224-8
1988, UK Prospective Diabetes Study. IV. Characteristics of newly presenting type 2 diabetic patients: Male preponderance and obesity at different ages. Multi-center Study, Diabet Med, 5, 154, 10.1111/j.1464-5491.1988.tb00963.x
Grundy, 1999, Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association, Circulation, 100, 1134, 10.1161/01.CIR.100.10.1134
Turner, 1998, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23), BMJ, 316, 823, 10.1136/bmj.316.7134.823
Walldius, 2001, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study, Lancet, 358, 2026, 10.1016/S0140-6736(01)07098-2
Lamarche, 1996, Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study, Circulation, 94, 273, 10.1161/01.CIR.94.3.273
Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk, Circulation, 82, 495, 10.1161/01.CIR.82.2.495
Coresh, 1993, Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women, J Lipid Res, 34, 1687, 10.1016/S0022-2275(20)35731-X
Khan, 2002, A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone, Diabetes Care, 25, 708, 10.2337/diacare.25.4.708
Boyle, 2002, Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records, Clin Ther, 24, 378, 10.1016/S0149-2918(02)85040-8
Gegick, 2001, Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice, Endocr Pract, 7, 162, 10.4158/EP.7.3.162
Mori, 1999, Effect of troglitazone on body fat distribution in type 2 diabetic patients, Diabetes Care, 22, 908, 10.2337/diacare.22.6.908
Nakamura, 2001, Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation—double-blind placebo-controlled trial, Diabetes Res Clin Pract, 54, 181, 10.1016/S0168-8227(01)00319-9
Miyazaki, 2002, Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients, J Clin Endocrinol Metab, 87, 2784, 10.1210/jcem.87.6.8567
Tolman, 2000, Thiazolidinedione hepatotoxicity: A class effect?, Int J Clin Pract Suppl, 113, 29
Jick, 1999, Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents, Diabetes Care, 22, 2067, 10.2337/diacare.22.12.2067
Luyckx, 2000, Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss, Diabetes Metab, 26, 98
Yu, 2002, Nonalcoholic fatty liver disease, Rev Gastroenterol Disord, 2, 11